Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.31 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3928099 | 0.98 | LMNA (0.39) | LMNANPSR1MAPTCYP4F2CYP4A11 | |
| SCHEMBL231396 | 0.89 | — | — | |
| SCHEMBL16112142 | 0.88 | LMNA (0.38) | LMNANPSR1 | |
| Hydrochloric Acid SCHEMBL27585730 | 0.86 | NPSR1 (0.41) | LMNANPSR1MAPTCYP4F2CYP4A11 | |
| Bromide SCHEMBL21798034 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL233616 | 0.86 | — | — | |
| 1-Aminocyclopropane Carboxylic Acid SCHEMBL22729882 | 0.80 | NSD2 (0.44) | LMNANPSR1ALDH1A1 | |
| SCHEMBL18440097 | 0.80 | NPSR1 (0.38) | LMNANPSR1CYP4F2CYP4A11 | |
| SCHEMBL1433032 | 0.79 | — | — | |
| SCHEMBL331908 | 0.79 | NPSR1 (0.50) | LMNANPSR1MAPTCYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025230799-A2 | CYCLOALKYL- AND PIPERIDINYL-CONTAINING DIAMINOMETHYLENE PYRIMIDINE-2,4,6-TRIONE AGONISTS OF PARATHYROID HORMONE 1 AND INCRETIN RECEPTORS | SEPTERNA, INC. (US) | 2025-11-06 | — | — | WO | disclosed |
| WO-2015185485-A1 | USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI | BASF SE (DE) | 2015-12-10 | — | — | WO | disclosed |
| US-8921380-B2 | Pyrazolo[1,5-a] pyrimidine compounds as CB1 receptor antagonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-12-30 | — | — | US | disclosed |
| WO-2014160649-A1 | HYDROXAMIC ACID DERIVATIVES AS LPXC INHIBITORS FOR THE TREATMENT OF BACTERIAL INFECTIONS | NOVARTIS AG (CH) | 2014-10-02 | — | — | WO | disclosed |
| EP-2520577-B1 | Pyrazolo[1,5-a]pyrimidine compounds as cb1 receptor antagonists | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-12-11 | — | — | EP | disclosed |
| EP-2035427-B1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | MITSUBISHI TANABE PHARMA CORP (JP) | 2013-12-11 | — | — | EP | disclosed |
| US-8569535-B2 | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI (FR) | 2013-10-29 | — | — | US | disclosed |
| US-8569535-B2 | Substituted benzoylamino-indan-2-carboxylic acids and related compounds | SANOFI (FR) | 2013-10-29 | — | — | US | disclosed |
| EP-2520577-A1 | Pyrazolo[1,5-a]pyrimidine compounds as CB1 receptor antagonists | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-20120202992-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | TANIMOTO KOICHI (JP) | 2012-08-09 | — | — | US | disclosed |
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | disclosed |
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2010-05-06 | — | — | US | disclosed |
| EP-2155711-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | Sanofi-Aventis (FR) | 2010-02-24 | — | — | EP | disclosed |
| US-20090258867-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-15 | — | — | US | disclosed |
| EP-2035427-A2 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | Mitsubishi Tanabe Pharma Corporation (JP) | 2009-03-18 | — | — | EP | disclosed |
| US-20090048256-A1 | Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-02-19 | — | — | US | disclosed |
| WO-2008151211-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | SANOFI-AVENTIS (FR) | 2008-12-11 | — | — | WO | disclosed |
| EP-1951678-A1 | PYRAZOLE COMPOUNDS HAVING CANNABINOID RECEPTOR (CB1) ANTAGONIZING ACTIVITY | Mitsubishi Tanabe Pharma Corporation (JP) | 2008-08-06 | — | — | EP | disclosed |
| WO-2008004698-A2 | PYRAZOLO [1, 5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-01-10 | — | — | WO | disclosed |
| WO-2007046550-A1 | PYRAZOLE COMPOUNDS HAVING CANNABINOID RECEPTOR (CB1) ANTAGONIZING ACTIVITY | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202992-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | CNR1, CNR2, CCKAR | LMNA 4794/4885NPSR1 48/4885MAPT 4458/4885 |
| US-20090258867-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | CNR1, CNR2, CCKAR | LMNA 4837/4885NPSR1 27/4885MAPT 4396/4885 |
| US-20090048256-A1 | Pyrazole Compounds Having Cannabinoid Receptor (CB1) Antagonizing Activity | CNR1, CNR2, OPRD1 | LMNA 4796/4885NPSR1 68/4885MAPT 4274/4885 |
| US-20100113462-A1 | SUBSTITUTED BENZOYLAMINO-INDAN-2-CARBOXYLIC ACIDS AND RELATED COMPOUNDS | CXCR5, CXCR1, CCR5 | LMNA 4505/4885NPSR1 110/4885MAPT 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.